News 11.06.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics and Orano Med, a clinical stage...
News 06.06.2024 Zurich, Switzerland – June 05, 2024 Microcaps AG, a leading innovator in advanced microencapsulation technology, today announced the successful completion of its Series A financing round, raising CHF 9.3 million. This significant capital increase marks a pivotal moment for the company as it aims to meet the growing demand for its...
News 06.06.2024 Topadur Pharma AG and Oshen Holdings SA have signed an agreement to develop the liquid topical formulation of TOP-M119 for treating alopecia. The contract covers co-development, licensing and commercialisation rights for Greater China, focusing initially on completing the IND studies and clinical phases I and II. The deal is based...
News 03.06.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it...
News 31.05.2024 ZURICH, Switzerland and NEWTON, Massachusetts, May 30, 2024 — GlobeNewswire — Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible,...